Literature DB >> 15677778

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

Niels H Andersen1, Per L Poulsen, Søren T Knudsen, Steen H Poulsen, Hans Eiskjaer, Klavs W Hansen, Kjeld Helleberg, Carl E Mogensen.   

Abstract

OBJECTIVE: To assess and compare the long-term effects of the combination of candesartan and lisinopril with high-dose lisinopril on systolic blood pressure in patients with hypertension and diabetes. RESEARCH DESIGN AND METHODS: This was a prospective, randomized, parallel-group, double-blind, double-dummy study with a 12-month follow-up. Drug therapy was either lisinopril 40 mg once daily or dual-blockade treatment with candesartan 16 mg once daily and lisinopril 20 mg once daily. The study comprised 75 type 1 and type 2 diabetic patients aged 35-74 years. The main outcome measures were seated and 24-h ambulatory systolic blood pressure.
RESULTS: Reduction in systolic blood pressure (24-h systolic blood pressure) reduction was obtained in both treatment arms (mean reduction at final follow-up: dual blockade 6 mmHg vs. lisinopril 2 mmHg), but no significant difference was found between dual-blockade and lisinopril 40 mg once daily (P = 0.10). Both treatments were generally well tolerated, and similar low rates of side effects were found in the two groups.
CONCLUSIONS: There was no statistically significant difference between lisinopril 40 mg once daily and lisinopril 20 mg in combination with candesartan 16 mg once daily in reducing systolic blood pressure in hypertensive patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677778     DOI: 10.2337/diacare.28.2.273

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  21 in total

Review 1.  Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.

Authors:  M Dalla Vestra; N Simioni; A Masiero
Journal:  Int Urol Nephrol       Date:  2008-10-29       Impact factor: 2.370

2.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

Review 3.  Blood pressure control for diabetic retinopathy.

Authors:  Diana V Do; Xue Wang; Satyanarayana S Vedula; Michael Marrone; Gina Sleilati; Barbara S Hawkins; Robert N Frank
Journal:  Cochrane Database Syst Rev       Date:  2015-01-31

4.  Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.

Authors:  Paweena Susantitaphong; Kamal Sewaralthahab; Ethan M Balk; Somchai Eiam-ong; Nicolaos E Madias; Bertrand L Jaber
Journal:  Am J Hypertens       Date:  2013-01-07       Impact factor: 2.689

Review 5.  The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

Review 6.  Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

Authors:  Peter N Van Buren; Robert Toto
Journal:  Adv Chronic Kidney Dis       Date:  2011-01       Impact factor: 3.620

Review 7.  Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

8.  Should ACE inhibitors and ARBs be used in combination in children?

Authors:  Brian R Stotter; Michael A Ferguson
Journal:  Pediatr Nephrol       Date:  2018-08-15       Impact factor: 3.714

Review 9.  Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?

Authors:  Kunal Chaudhary; Ravi Nistala; Adam Whaley-Connell
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

10.  Arterial hypertension in diabetes mellitus: from theory to clinical practice.

Authors:  C Sampanis; C Zamboulis
Journal:  Hippokratia       Date:  2008-04       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.